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Abstract
Background—New hepatitis C virus (HCV) treatments deliver higher cure rates with fewer 
contraindications, increasing demand for treatment and healthcare costs. The cost-effectiveness of 
new treatments is unknown.
Methods—We conducted a microsimulation of guideline testing followed by alternative 
treatment regimens for HCV among the US population aged 20 and older to estimate cases 
identified, treated, sustained viral response, deaths, medical costs, quality-adjusted life-years 
(QALYs), and the incremental cost-effectiveness ratio (ICER) of different treatment options 
expressed as discounted lifetime costs and benefits from the healthcare perspective.
Results—Compared to treatment with pegylated interferon and ribavirin (PR), and a protease 
inhibitor for HCV genotype (G) 1 and PR alone for G2/3, treatment with PR and Sofosbuvir (PRS) 
for G1/4 and treatment with Sofosbuvir and ribavirin (SR) for G2/3 increased QALYs by 555 226, 
reduced deaths by 80 682, and increased costs by $26.2 billion at an ICER of $47 304 per QALY 
gained. As compared to PRS/SR, treating with an all oral regimen of Sofosbuvir and Simeprevir 
(SS) for G1/4 and SR for G2/3, increased QALYs by 1 110 451 and reduced deaths by an 
additional 164 540 at an incremental cost of $80.1 billion and an ICER of $72 169. In sensitivity 
analysis, where treatment with SS effectiveness was set to the list price of Viekira Pak and then 
Harvoni, treatment cost $24 921 and $25 405 per QALY gained as compared to PRS/SR.
Conclusions—New treatments are cost-effectiveness per person treated, but pent-up demand for 
treatment may create challenges for financing.
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In 2012, the US Centers for Disease Control and Prevention (CDC) recommended that 
Americans born during 1945–1965 receive a 1-time antibody test to identify hepatitis C 
virus (HCV) infection (birth-cohort testing) [1–3]. In 2013, this recommendation was 
affirmed by the United States Preventive Services Task Force citing the large health benefits 
of birth-cohort testing predicted by modeling studies [2-6]. From 2011 to 2013, at least 6 
published studies found HCV testing and treatment to be cost-effectiveness, using different 
parameters and assumption [2,4,6-9]. Adjusting the aggregate results from these studies into 
per person incremental costs and quality-adjusted life-years (QALYs) allows for the visual 
comparison of their results (Figure 1).
Since publication of the birth-cohort testing recommendations, new highly effective drugs 
have been released, and clinical treatment recommendations have been updated to 
incorporate their use [10]. In this article, we modified a previously published model of the 
cost-effectiveness of birth-cohort testing to assess the cost-effectiveness, financial impacts, 
and health benefits of birth-cohort testing using new treatments under the assumption of 
broad population-based implementation [2].
METHODS
Decision Analytic Model
We programmed (Microsoft Visual Studio 2010, Redmond, Washington) a Monte Carlo 
simulation model of the natural history of hepatitis C with antibody prevalence estimates 
stratified by age, gender, race/ethnicity, and history of injecting drugs. The model’s natural 
history, validation, and economic parameters have been previously described, and revisions 
to the model’s parameters are included in Tables 1 and 2 and technical documentation [2, 
52]. Compared to previous versions, the model’s structure now assumes that a sustained 
viral response (SVR) results in a reduced risk of hepatocellular carcinoma (HCC) instead of 
risk elimination. Additional information is included in the technical report, available as 
Supplementary materials.
Model Cohorts
We modeled the US population aged 20 or older, totaling 229 185 985 in 2012 [62]. We 
stratified the population based on age, sex, and lifetime risk of injecting drugs [63].We 
further stratified these cohorts into those with and without antibody to HCV (based on year 
of birth), and those with antibodies into those with chronic (78%) and cleared (22%) 
infections [64]. We assumed 25% of chronically infected patients were not interested in 
treatment or were not reachable by the healthcare system and assumed the remainder would 
be offered testing [35, 36, 40, 65].
We estimated starting fibrosis rates using data from biopsy results of newly diagnosed 
patients observed in the retrospective component of the Birth-cohort Evaluation to Advance 
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Screening and Testing for Hepatitis C (BEST-C) study [66]. We used census life tables to 
calculate the annual probability of mortality from nonhepatic causes and assigned a relative 
risk of mortality of 1.42 for individuals who reported ever injecting drugs [2, 67].
Screening and Treatment Scenarios
For the purpose of our simulation, we assumed that 18.5% of those outside the 1945 to 1965 
birth-cohort would be offered testing and that 100% of those in the birth-cohort would be 
offered testing if they could be reached through the health system. Of those who accepted 
testing and tested positive for HCV RNA, we compared the cost-effectiveness and health 
impacts of 5 treatment alternatives: (1) No treatment (NT); (2) Pegylated interferon and 
ribavirin (PR) for 48 weeks for genotypes 1 and 4, and for 24 weeks for genotypes 2 and 3; 
(3) PR for 24 weeks plus an additional protease inhibitor (PRPI) for 12 weeks for genotypes 
1 and 4 or PR for 24 weeks for genotypes 2 and 3; (4) PR plus Sofosbuvir (PRS) for 12 
weeks for genotypes 1 and 4, Sofosbuvir plus ribavirin (SR) for 12 weeks for genotype 2, 
and SR for 24 weeks for genotype 3; or (5) Simeprevir and Sofosbuvir (SS) for 12 weeks for 
genotypes 1 and 4, SR for 12 weeks for genotype 2, and SR for 24 weeks for genotype 3. We 
assumed all treatments occurred in the first year of the simulation. These treatments are 
consistent with those evaluated by major medical societies in creating their HCV treatment 
guidelines [10]. Although guidelines discourage the use of older line treatments, we include 
them to facilitate comparisons with other studies. We also separately report preliminary 
incremental cost-effectiveness ratio (ICER) estimates for interferon-free combination of 
ledipasvir and sofosbuvir and the drugs in viekira pak, which were approved after initial 
submission of this article.
Screening, Contraindication, and Antiviral Initiation
We assumed that 91% of those offered testing would accept and 90% of those who tested 
positive would receive their result and be evaluated for treatment [37]. To estimate the 
proportion of patients who would receive treatment we conducted a meta-analysis of rates of 
treatment found across 12 published studies of community treatment of patients with HCV 
infection only [14–25]. We estimated the proportion who would be treated with pegylated 
interferon based treatments (0.242) and its credible interval (0.228–0.251) using Monte 
Carlo Markov Chain (MCMC) simulation methods programmed with Proc MCMC of the 
SAS 9.2 Software (SAS Institute, Cary, North Carolina) [68]. We also estimated the 
proportion of persons who would be treated (0.719) with nonpegylated interferon-based 
treatments and its credible interval (0.66–0.77).
Effectiveness, Cost, and Benefit of Antiviral Therapy
Older forms of treatment have exhibited lower rates of real world effectiveness and cost than 
in clinical trial data, but real-world data are not yet available for newer treatments. To enable 
equivalent comparisons we used clinical trial estimates of efficacy and published package 
estimates of cost for all treatments. The benefit of successful treatment was an SVR that 
varied with treatment type and virus genotype. For pegylated interferon based treatments, we 
also assumed a quality adjusted life year decrement that varied with the duration of 
treatment. We assumed an SVR eliminated fibrosis progression associated with chronic 
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HCV infection. For patients with cirrhosis, we assumed an SVR was also associated with a 
relative risk of HCC of 0.24 [34].
Testing and Medical Treatment Costs
We set the cost of testing via routine risk-based assessments to $24.65 per person tested, 
equal to the incremental costs of testing using an electronic health record prompt system in 
an unpublished CDC study. Diagnosed patients who did not undergo antiviral therapy or 
achieve an SVR were assumed to receive HCV-related medical management, with costs per 
stage estimated as the average costs used across seven previously published cost-
effectiveness studies [2, 4, 6–9, 53]. Patients who achieved an SVR accrued annual 
monitoring costs. Nontreatment clinical management increased costs without increasing 
benefits.
Utility Losses
Uninfected persons were assigned annual QALY values that decreased with age to account 
for other health conditions [69]. For persons with HCV, we collected utility losses from 5 
studies across 7 HCV states: SVR, METAVIR 0–1, METAVIR 2–3, compensated cirrhosis, 
DCC, HCC, and post-liver transplant then summarized the scores as reported elsewhere [2, 
69–74]. Annual QALYs for patients on pegylated interferon-based therapy were multiplied 
by 0.85 adjusting for treatment duration [13].
Simulation, Outcomes, and Sensitivity Analysis
We estimated medical outcomes, costs, and QALYs associated with each scenario 
accounting for uncertainty in each of the model’s key parameters using probabilistic 
sensitivity analysis, reporting the mean and the empirical 95% credible interval for each 
outcome. We estimated the ICER for routine and birth-cohort testing combined followed by 
each treatment scenario as compared to the next most costly alternative. For PRS/SR and for 
SS/SR, we estimated the ICER of immediate treatment compared to no treatment (NT; 
scenario 1) for people in METAVIR stages F0, F1, F2, F3, and F4. For PRS/SR compared to 
PRPI and for SS/SR compared to PRS/SR we tested the univariate sensitivity of the ICER to 
uncertainty in the model’s key parameters by evaluating results based on the upper and 
lower bounds of the 95% confidence interval of each parameter included in Tables 1 and 2.
We estimated the cost of treatment for SS/SR at which the ICER was equal to $50 000 per 
QALY gained compared to PRS/SR and compared to NT. Compared to NT, we estimated the 
treatment cost at which the ICER of PRS/SR and SS/SR was equal to $50 000 per QALY 
gained for patients treated at stages F0 and F1.
For all patients, we estimated the cost-effectiveness of SS/SR compared to PRS/SR and to 
NT when the cost of SS was set to the list price of Viekira Pak ($83 319) and the list price of 
Harvoni ($94 500). We provide only limited results for these scenarios, because these 
treatments were released during this manuscript’s review process.
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RESULTS
Of the 229.2 million Americans aged ≥20 years in 2012, we estimated 3.7 million were 
antibody positive for HCV, 2.9 million were chronically infected, and that 1.5 million would 
be identified through testing prior to the development of end-stage liver disease or death 
from other causes. With no testing or treatment (scenario 1), we estimated that 1.18 million 
of those chronically infected (41.1%) would develop DCC or HCC and die in those states 
prior to model termination at age 100 (Table 3). For comparison to other studies, the model’s 
45-year mortality rate was 18.7% assuming age of infection of 25 years and a starting 
fibrosis state of F0. With no testing or treatment, currently infected patients were expected to 
generate $100.3 billion in discounted hepatitis C medical costs during their lifetimes.
The Health Benefits and Cost Impacts of Treatment Scenarios
With testing and PR treatment (scenario 2), 356 657 patients were treated of whom 156 880 
achieved an SVR reducing the number of HCV-associated deaths from 1 181 554 to 1 131 
638, a reduction of 49 916 deaths compared to NT. Compared to NT, testing followed by PR 
treatment increased QALYs by 306 537 and medical costs by $18.3 billion. With the same 
number of patients treated as compared to NT, PRPI (scenario 3) increased patients 
achieving an SVR by 237 618 and reduced the number of deaths from HCV to 1 106 130, a 
reduction of 75 424 deaths. Compared to NT, PRPI increased QALYs by 477 066 and 
increased medical costs by $20.8 billion. With testing and PRS/SR treatment (scenario 4), 
541 136 patients were treated of whom 489 573 achieved an SVR reducing the number of 
deaths from HCV by 156 106 compared to NT. Compared to NT, PRS/SR increased QALYs 
by 1 032 292 and increased and medical costs by $47.0 billion. Finally, with testing and 
SS/SR treatment (scenario 5), 1 057 148 patients were treated of whom 1 010 225 achieved 
an SVR reducing the number of deaths from HCV by 320 646 compared to NT. Compared 
to NT, SS/SR increased QALYs by 2 142 743 and medical costs by $127.1 billion.
Incremental Cost-effectiveness
The ICER of PR vs NT was $59 792 per QALY gained (Table 3). PR was extendedly 
dominated by PRPI. Compared to NT, the ICER of PRPI was $43 530 per QALY gained, 
PRS/SR cost $47 237 per QALY gained compared to PRPI, and SS/SR cost $72 169 per 
QALY gained compared to PRS/SR. Compared to NT, the incremental cost per QALY 
gained was $59 792 for PR, $43 530 for PRPI, $45 524 for PRS/SR, and $59 333 for SS/SR.
SENSITIVITY ANALYSES
Compared to NT, the ICER of both PRS/SR and SS/SR was sensitive to the fibrosis stage at 
the time of treatment, from $173 800 per QALY gained for SS/SR at stage F0 to $13 000 per 
QALY gained for PRS/SR for patients with cirrhosis (Figure 2). The ICER of PRS/SR 
compared to PRPI was most sensitive to the cost of PRS/SR treatment, QALY improvements 
assumed to occur after an SVR, the speed of fibrosis progression, QALY losses associated 
with moderate fibrosis (F2, F3) and cirrhosis (F4), the medical cost of DCC, the probability 
of an SVR for PRS/SR, and the risk reduction of HCC among people with cirrhosis who had 
achieved an SVR (Figure 3A and 3B). No other parameter in the model changed the ICER 
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by more than 5% when set to the bounds of its 95% confidence interval. The ICER of SS/SR 
compared to PRS/SR was sensitive to similar variables (cost of treatment, QALY losses 
associated with infection prior to end stage disease, the probability of an SVR, and the 
impact of an SVR on reducing HCC).
The ICER of SS/SR compared to PRS/SR fell to $50 000 per QALY gained at a treatment 
cost of $136 000. Compared to NT, the ICER of SS/SR was equal to $50 000 per QALY 
gained at a treatment cost of $139 000. Assuming the same level of effectiveness, SS/SR 
cost $24 921 per QALY gained compared to PRS/SR and $31 828 compared to NT at the 
price of Viekira Pak, and $25 405 per QALY gained compared to PRS/SR and $35 100 
compared to NT at the list price of Harvoni.
Compared to NT, treating patients at stage F0 with PRS/SR would need to cost $37 600 to 
achieve an ICER of $50 000 per QALY; $47 000 for treatment with SS/SR. Also as 
compared to NT, treating patients at stage F1 with PRS/SR would need to cost $73 000 to 
achieve an ICER of $50 000 per QALY; $82 000 for treatment with SS/SR.
CONCLUSIONS
Our estimates indicate that the treatment alternatives for HCV of pegylated interferon 
combined with ribavirin and Sofosbuvir, and the all-oral combinations of Sofosbuvir and 
Simeprevir increase QALYs compared to their alternatives at a cost of $47 237 per QALY 
gained for PRS/SR and $72 169 per QALY gained for SS/SR. During review of this article, 
two interferon-free combination treatments were approved for the treatment of genotype 1 
HCV patients (Harvoni and Viekira Pak) with lower list prices ($94 500 and $83 319) 
compared to SS/SR. Assuming an equal effectiveness for these combinations as for SS, the 
lower prices would result in cost-effectiveness of approximately $25 000 per QALY gained 
for new treatments compared to PRS/SR, and of approximately $32 000 to $35 000 per 
QALY gained compared to NT. Potentially lower prices would improve treatment cost-
effectiveness further.
However, financing the treatment of all Americans who could benefit from antiviral therapy 
will be a continuing challenge given the number of individuals who are undiagnosed, 
untreated, or failed to respond to older treatment regimens. In addition, simply linking 
diagnosed patients to clinical settings in which they can be evaluated for treatment remains 
an ongoing challenge that is likely to reduce the potential benefits and costs of new 
treatments for the foreseeable future [75, 76].
Still our estimates indicate achieving modest identification and treatment benchmarks (1.06 
million chronically infected individuals) could increase QALYs by over 2.1 million, 
decrease deaths from HCV by over 320 000, but also increase lifetime costs. Increased costs 
are a function of both the unit costs of new treatments that are declining as new drugs enter 
the market, and also the greater number of individuals that can tolerate all-oral regimens. 
Given the current difficulties of linking patients to care, the incremental costs of new 
treatments are likely to accrue over time and may be reduced as more treatments are 
approved for use and insurers negotiate discounts for their plan members. Our sensitivity 
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analyses indicate that ICER of PRS/SR compared to PRPI and of SS/SR were highly 
sensitive to the costs of treatment. Lower costs (especially for all-oral regimens) would 
increase their cost-effectiveness and alleviate financing pressures.
Our sensitivity analyses also indicate that cost-effectiveness is sensitive to the stage at which 
a patient is treated. Treating with SS/SR costs $173 796 per QALY gained for people with a 
current fibrosis status of F0 compared to only $35 884 for patients in F3. However, this 
finding must be understood in context of our lack of knowledge of the health and cost 
impacts of chronic infection prior to the development of end-stage liver disease and the 
limited ability to identify patients’ stage of liver fibrosis without the use of biopsy.
Limitations
Our study is limited by at least the following factors. First, we made a number of 
assumptions regarding the utilization of new treatments. Because the number of people who 
will seek care is unknown, we assumed that 25% of the population would be beyond the 
reach of the healthcare system. Given the current difficulties of linking identified individuals 
to clinical care, this number may be optimistic. To simplify estimation, we further assumed 
that all patients who received treatment would do so in the base year of the simulation. 
Compared to an alternative that treats all patients over time and assumes no missed 
opportunities to prevent disease, this limitation has the effect of making treatment appear 
more costly and less cost-effective as NT costs are discounted, and NT is averted due to 
death from non-HCV causes. Finally, we estimated the rates of interferon-based treatment 
uptake using data from studies prior to the inclusion of more effective agents, and made 
assumptions about how treatment rates would increase with interferon-free treatment. 
Sensitivity analyses indicate these assumptions do not have a large impact on cost-
effectiveness; however, lower treatment uptake will lower the aggregate health benefits and 
costs reported for each scenario.
Second, our cost-effectiveness results are partially determined by the model’s distribution of 
starting fibrosis rates which were derived from primary biopsy data from newly diagnosed 
patients. While, we believed these are superior to previously used simulated estimates, data 
on this parameter are sparse, and treatment will be less cost-effective if undiagnosed patients 
have milder progression. However, our sensitivity analyses estimate the cost-effectiveness of 
treatment at different stages of progression and indicate that treatment at earlier fibrosis 
stages is still moderately cost-effective compared to NT (at F1, $73 906 per QALY gained 
for PRS/SR, and $93 236 for SS/SR compared to NT). Updates to medical treatment 
guidelines call for prioritizing treatment in patients who are F1 or higher.
Our article reports an overall mortality rate of 41% among prevalent hepatitis C cases given 
NT, a rate higher than reported in earlier model publications [2, 21]. This higher rate of 
mortality results from the use of a longer time horizon in this paper (until age 100). Our 
model’s 45-year mortality rate is identical to that from previous work [2].
Our model excludes the treatment benefits of averting secondary transmissions. Although 
such benefits remain hypothetical, modeling studies suggest that treatment reduces 
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transmission especially among people who inject drugs [77]. The limitation results in a less 
favorable ICER than had these benefits been included.
Finally, ICER by fibrosis stage estimates assumes that fibrosis level can be reliably 
ascertained in clinical settings, although performing biopsies among all patients is likely 
unethical. Although nonbiopsy ascertainment methods like AST/Platelet Ratio Index 
(APRI), Fibrosis-4 scoring, and elastography are improving, they cannot yet reliably 
differentiate between pre-cirrhosis fibrosis stages.
Implications
New treatments for HCV infection have the potential to provide substantial public health 
benefits at a reasonable cost per patient treated. However, the high number of untreated 
hepatitis C patients creates financing challenges that need to be overcome.
Supplementary Material
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Figure 1. 
Estimated incremental change in per person costs and per person quality-adjusted life-years 
estimated across 9 published scenarios that tested population hepatitis C virus testing 
followed by treatment. Abbreviations: PR, pegylated interferon and ribavirin; QALY, 
quality-adjusted life-year.
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Figure 2. 
Incremental cost-effectiveness by liver fibrosis score as measured by METAVIR score. 
Abbreviations: ICER, incremental cost-effectiveness ratio; PRS/SR, pegylated interferon, 
ribavirin and sofosbuvir for genotypes 1 and 4, and sofosbuvir and ribavirin for genotypes 2 
and 3; SS/SR, sofosbuvir and simeprevir for genotypes 1 and 4, and sofosbuvir and ribavirin 
for genotypes 2 and 3.
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Figure 3. 
A, Univariate sensitivity to changes in key model parameters of pegylated interferon, 
ribavirin, and sofosbuvir treatment for G1 and sofosbuvir/ribavirin treatment for G2 and 3 
compared to pegylated interferon, ribavirin, and protease inhibitor treatment for G1 and 
pegylated interferon and ribavirin for G2 and 3. B, Univariate sensitivity to changes in key 
model parameters of sofosbuvir and simeprevir treatment for G1 and sofosbuvir/ribavirin 
treatment for G2 and 3 compared to pegylated interferon, ribavirin, and sofosbuvir treatment 
for G1 and sofosbuvir/ribavirin treatment for G2 and 3. Univariate sensitivity analysis 
included all parameters from Tables 1 and 2. Tested ranges based on the upper and lower 
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95% confidence interval bound for each parameter. Only parameters with a >5% impact on 
ICER are shown. Assumes birth cohort testing is implemented. Abbreviations: DCC, 
decompensated cirrhosis; ICER, incremental cost-effectiveness ratio; QALY, quality-
adjusted life-year; SVR, sustained viral response.
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Table 1
Treatment Parameters and Costs
Parameter Value 95% Interval Used in Simulation Source Distribution
Genotype 1&4: Peglyated Interferon + Ribavirin (48 wks)
 Applicable Scenarios 2
 Probability of SVR 0.358 32.5%–39.0% [11] Beta
 Cost of treatment $61 224 $47 525–$78 870 [12] Lognormal
 Treatment year utility 0.882 0.852–0.912 [13] Uniform
 Proportion Treated 0.24 0.228–0.251 [14–25] Beta
Genotype 1&4: Protease Inhibitor (12 wks) + Peglyated Interferon + Ribavirin (24 wks)
 Applicable Scenarios 3
 Probability of SVR 0.665 0.607–0.724 [11] Beta
 Cost of treatment $78 812 $61 178–$101 528 [12, 26] Lognormal
 Treatment year utility 0.968 0.853–0.912 [13] Uniform
 Proportion Treated 0.24 0.228–0.251 [14–25] Beta
Genotype 1&4: Sofosbuvir + Peglyated Interferon + Ribavirin (12 wks)
 Applicable Scenarios 4
 Probability of SVR 0.902 0.856–0.926 [27] Beta
 Cost of treatment $99 306 $77 087–$127 929 [12, 28] Lognormal
 Treatment year utility 0.966 0.957–0.974 [13] Uniform
 Proportion Treated 0.24 0.228–0.251 [14–25] Beta
Genotype 1&4: Sofosbuvir+ Simeprevir (12 wks)
 Applicable Scenarios 5
 Probability of SVR 0.963 0.869–0.998 [29] Beta
 Cost of treatment $150 360 $116 718–$193 698 [28, 30] Lognormal
 Treatment year utility 1.00 … Assumption NA
 Proportion Treated 0.72 0.66–0.77 [14–25] and assumptions Beta
Genotype 2: Peglyated Interferon + Ribavirin (24 Wks)
 Applicable Scenarios 1, 2
 Probability of SVR 0.67 0.607–0.724 [27] Beta
 Cost of treatment $30 612 $23 723–$39 435 [12] Lognormal
 Treatment year utility 0.968 0.960–0.975 [13] Uniform
 Proportion Treated 0.24 0.228–0.251 [14–25] Beta
Genotype 2: Sofosbuvir + Ribavirin (12 wks)
 Applicable Scenarios 3, 4, 5
 Probability of SVR 0.971 0.922–0.996 [27] Beta
 Cost of treatment $88 158 $68 443–$113 568 [12, 28] Lognormal
 Treatment year utility 1.00 … Assumption NA
 Proportion Treated 0.72 0.66–0.77 [14–25] and assumptions Beta
Genotype 3: Peglyated Interferon + Ribavirin (24 Wks)
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Parameter Value 95% Interval Used in Simulation Source Distribution
 Applicable Scenarios 1, 2
 Probability of SVR 0.67 0.607–0.724 [27] Beta
 Cost of treatment $30 612 $23 723–$39 435 [12] Lognormal
 Treatment year utility 0.9655 0.960–0.975 [13] Uniform
 Proportion Treated 0.24 0.228–0.251 [14–25] Beta
Genotype 3: Sofosbuvir + Ribavirin (24 wks)
 Applicable Scenarios 3, 4, 5
 Probability of SVR 0.848 0.801–0.889 [31] Beta
 Cost of treatment $176 316 $136 866–$227 135 [12, 28] Lognormal
 Treatment year utility 1.00 … Assumption NA
 Proportion Treated 0.72 0.66–0.77 [14–25] and assumptions Beta
Abbreviations: NA, not applicable; SVR, sustained viral response.
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Table 2
Key Nontreatment Parameters
Parameter Value
95% Interval Used in 
Simulation Source Distribution
Population Size (ages 20 to 90) 229 185 985 … US Census 2012 age 20 + 
population estimate
…
Proportion reachable through health 
system
0.75 … Assumption …
Screening and Treatment Probabilities
 Screening probability if screening 
intervention is not offered
0.18 … [32] Beta
 Ribonucleic acid test acceptance 
probability
1 … Assumption …
 Return for anti-HCV results probability 0.9 … [33] Beta
 Probability of viral clearance rate given 
antibody positive status
0.22 … [34] Beta
 Probability of being considered for 
treatment
1 … Assumption …
 Proportion treated for regimens 
including Pegylated Interferon
0.24 0.23–0.25 [14–21, 35–38] Beta
 Proportion treated for regimens 
excluding Pegylated Interferon
0.72 0.66–0.77 [14–25] and assumptions Beta
Proportion of Background QALYs retained at Each Disease Stage
 No HCV 1 … See text …
 SVR 0.93 0.91–0.95 Uniform
 Chronic HCV METAVIR—0 0.93 0.91–0.95 Uniform
 Chronic HCV METAVIR—1–2 0.86 0.83–0.90 Uniform
 Chronic HCV METAVIR—2–3 0.83 0.79–0.87 Uniform
 Compensated cirrhosis 0.81 0.77–0.85 Uniform
 Decompensated cirrhosis 0.7 0.63–0.78 Uniform
 HCC 0.67 0.60–0.74 Uniform
 Prior transplant 0.78 0.73–0.83 Uniform
Annual Probability of Complications from Cirrhosis
 HCC 0.025 0.022–0.028 [39] Beta
 Decompensated cirrhosis 0.039 0.035–0.043 [40] Beta
 Transplant given HCC or decompensated cirrhosis 0.031 0.029–0.033 [41, 42] Beta
 Relative risk of HCC after SVR 0.24 0.183–0.315 [43] Lognormal
 Annual Probability of Death from 
Complications
 HCC 0.409 0.368–0.450 [44] Beta
 Decompensated cirrhosis 0.135 0.122–0.149 [45] Beta
 Transplant first year 0.14 0.126–0.154 [47] Beta
 Transplant years 2–4 0.038 0.035–0.042 [47] Beta
 Transplant years 5–15 0.025 0.023–0.027 [48] Beta
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Parameter Value
95% Interval Used in 
Simulation Source Distribution
 Transplant years 16–18 0.014 0.012–0.015 [48] Beta
 Relative annual risk of mortality for 
IDUs—20–39 y old
2.13 … [49] Lognormal
 Relative annual risk of mortality for 
IDUs—40 and older
1.42 … [49] Lognormal
Costs
 Screening
  Antibody Testing $24.65 $19.09–$31.82 Unpublished CDC Data Lognormal
  Cost of RNA testing $58.88 $45.61-$76.01 [46] Lognormal
 Medical
  Cost of post-diagnostic evaluation, if coordinated $831.63 
with treatment
$644.18–1,073.63 [4, 7–9, 50, 51] Lognormal
  Antiviral treatment See Table 1
 Non-antiviral Medical Care
  Cost of post-diagnostic evaluation 
after diagnosis if not treated
$869.19 $673.27–1,122.11 [4, 7–9, 50, 51] Lognormal
  HCV costs for METAVIR stages 0–4, 
w/out antiviral treatment
$753 $583.27-$972.11 [6, 52–57] Lognormal
  HCV cost of compensated cirrhosis 
w/out antiviral treatment
$1433 $1,110.00–$1,849.99 [6, 52–57] Lognormal
  HCV cost of decompensated cirrhosis 
w/out antiviral treatment
$19 317 $11,152.79-$33,457.69 [6, 52–57] Lognormal
  Cost of HCC $40 663 $23,477.03-$70,429.67 [6, 52–57] Lognormal
  Cost in Years After SVR $224.88 $174.19–$290.32 [4, 7–9, 50, 51] Lognormal
  Cost of liver transplant (year of) $190 301 $109,871.44–$329,607.67 [4, 6–9, 52, 53] Lognormal
  Cost of liver transplant (subsequent 
years)
$34 369 $19,843.15-$59,528.25 [4, 6–9, 52, 53] Lognormal
Prevalence rates
 Hepatitis C infection Varies by Birth 
Decade, Race, 
and Sex. See 
Technical 
Report
[58] Lognormal
 Heavy alcohol use (>4 drinks/day) 0.089 0.089–0.090 [59] Beta
 HIV+ 0.0205 0.020–0.021 [59] Beta
 Viral Type 1, black race 0.900 0.794–0.970 [60] Beta
 Viral Type 1, race other than black 0.700 0.628–0.768 [60] Beta
 Prevalence of IDU Varies by Birth 
Decade. See 
Technical 
Report
[58] Lognormal
METAVIR level at diagnosis
 METAVIR 0–1 0.107 … Unpublished CDC Data …
 METAVIR 1–2 0.357 … Unpublished CDC Data …
 METAVIR 2–3 0.232 … Unpublished CDC Data …
 METAVIR 3–4 0.143 … Unpublished CDC Data …
Clin Infect Dis. Author manuscript; available in PMC 2018 January 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Rein et al. Page 21
Parameter Value
95% Interval Used in 
Simulation Source Distribution
 METAVIR 4+ 0.161 … Unpublished CDC Data …
Annual Incremental Increase in METAVIR Score Units
 Relative METAVIR rate increase for 
patients infected with HIV, regardless of 
age, gender, or alcohol use status
2.00 … [39] …
 Infected under age 40
 Male, alcohol 0.154 0.125–0.167 [61] Lognormal
  Male, no alcohol 0.111 0.091–0.130 [61] Lognormal
  Female, alcohol* 0.095 0.088–0.100 [61] Lognormal
  Female, no alcohol 0.095 0.088–0.100 [61] Lognormal
 Infected age 40 or older [61]
  Male, alcohol 0.267 0.200–0.0500 [61] Lognormal
  Male, no alcohol 0.301 0.235–0.333 [61] Lognormal
  Female, alcohol 0.267 0.200–0.0500 [61] Lognormal
  Female, no alcohol 0.200 0.167–0.250 [61] Lognormal
  Annual discount rate 0.03 Not applicable Assumed Did not vary
Abbreviations: HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IDU, injection drug use; QALY, 
quality-adjusted life-year; SVR, sustained viral response.
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